MR Cancer Group
The MR Cancer Group at NTNU, headed by Professor Tone F. Bathen, focuses on the use of magnetic resonance imaging (MRI) and spectroscopy in identification of the functional and metabolic changes that precede anatomic evidence of cancer disease.
The group, which was founded by Professor Ingrid S. Gribbestad, is internationally recognised as one of the most experienced in large-scale tissue analyses and has long experience with functional MR imaging in cancer diagnostics.
Our long-term objective is to improve and individualise cancer treatment by developing integrated MR methods and data analysis tools for functional and molecular assessment of tumours.
We use a broad spectrum of systems for cancer studies, spanning from cultured cancer cells to humans, and have access to dedicated MR equipment for in vitro, ex vivo, preclinical and clinical research.
- Hvem må behandles for prostatakreft - in Norwegian (Sep 2017)
- Medisinstudent med to studier på kreftkongressen - in Norwegian (Jun 2017)
- Forsker på vektøkning hos brystkreft-opererte - in Norwegian (Jun 2017)
- Den mest vanlige kreftformen rammer bare menn - in Norwegian (Nov 2016)
- Movember news - in Norwegian (Nov 2016)
- Hva skjer egentlig i kreftsvulsten? - in Norwegian (Nov 2016)
- Brystkreftforsker Tonje Husby Haukaas - in Norwegian (Oct 2016)
- Pasienter skal bidra i kreftforskning - in Norwegian (Jul 2016)
- Kreftpasienter skal hjelpe forskerne - in Norwegian (Jul 2016)
- Advances in NMR metabolomics: an interview with Professor Tone F. Bathen (Apr 2016)
- Trond Mohn gir 40 millioner til NTNU - in Norwegian (Feb 2015)
- Nærmare behandling for aggressiv brystkreft - in Norwegian (Oct 2014)
- Radioaktivt stoff skal gjøre det enklere å behandle prostatakreft - in Norwegian (Sept 2014)
- Ny studie kan endre prostatakreftsjekk - in Norwegian (Apr 2014)